Management ChangeApr 14, 2026, 04:37 PM
Hepion Pharma Finalizes Separation Agreement with Former CEO
AI Summary
Hepion Pharmaceuticals, Inc. entered into a separation agreement with its former CEO, Dr. Kaouthar Lbiati, on April 13, 2026. The agreement includes a severance payment of $225,000, a pro-rata cash bonus of $30,625, and 6 months of COBRA payment reimbursements. Dr. Lbiati also resigned from the company's board of directors on the same date.
Key Highlights
- Dr. Kaouthar Lbiati received $225,000 in severance.
- She received $30,625 as a pro-rata cash bonus.
- The company will reimburse COBRA payments for 6 months.
- Dr. Lbiati resigned as a director on April 13, 2026.
Price Impact
More from HEPA